Imfinzi 120mg Injection Global Supply Framework
π Global Procurement Overview
Are you searching for a tightly regulated, cold-chain compliant international distribution partner to secure specialized oncology immunotherapies?
Ernest Impex (the premier global distribution division operating under the Group of Ernest Pharmaceutical Pvt. Ltd.) stands as a leading international exporter, bulk supplier, and licensed supplier of Imfinzi 120mg Injection (Durvalumab). Marketed by AstraZeneca Pharma India Ltd., Imfinzi represents a highly demanded checkpoint inhibitor across the global oncology care pathway.
π¬ Technical Product Profile & Long Information: Imfinzi 120mg
Imfinzi 120mg is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution formulated for intravenous (IV) infusion. The active constituent molecule is Durvalumab, a human immunoglobulin G1 kappa (IgG1ΞΊ) monoclonal antibody engineered via recombinant DNA technology.
.
βοΈ Mechanism of Action (How it Operates)
Imfinzi 120mg works as a precise immune checkpoint blocking agent by executing a highly focused biological pathway:
Blocking the PD-L1 Pathway: Tumors frequently exploit physiological checkpoints to escape detection.
Cancer cells express Programmed Death-Ligand 1 (PD-L1), which binds to PD-1 and CD80 receptors on T-cells, effectively sending an "off" signal that suppresses the T-cell's ability to attack the tumor. Enabling T-Cell Activation: Durvalumab binds directly and selectively to the PD-L1 protein, completely blocking its interactions with both PD-1 and CD80 receptors.
Immune Re-Activation: By lifting this molecular cloaking mechanism, Imfinzi releases the brake on the patientβs adaptive immune framework. The re-energized cytotoxic T-lymphocytes are then able to recognize, target, infiltrate, and eliminate the malignant cells effectively.
π Therapeutic Indications
Imfinzi 120mg single-use vials are globally procured and utilized across major clinical regimens, including:
Non-Small Cell Lung Cancer (NSCLC): Prescribed as a baseline monotherapy for adult patients with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
It is also deployed in combination with platinum chemotherapy for resectable and metastatic lines. Small Cell Lung Cancer (SCLC): Administered as a first-line treatment option in combination with etoposide and either carboplatin or cisplatin for adult patients diagnosed with extensive-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancer (BTC): Sourced in combination with gemcitabine and cisplatin for the frontline management of patients with locally advanced or metastatic biliary tract malignancies.
Hepatocellular Carcinoma (HCC): Indicated either as a standalone agent or in a combined regimen with tremelimumab for adult patients presenting with unresectable hepatocellular carcinoma.
Endometrial & Bladder Cancers: Sourced for specialized clinical settings addressing advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer and specific urothelial carcinoma lines.
β οΈ Side Effects & Safety Profile
As a highly systemic monoclonal antibody that modulates the bodyβs natural immune responses, Imfinzi 120mg can cause a range of side effects, requiring vigilant clinical observation:
Common Systemic Reactions: Deep fatigue, persistent cough, dyspnea (shortness of breath), upper respiratory tract infections, rash, nausea, decreased appetite, and peripheral edema.
Immune-Mediated Adverse Reactions (IMARs): Because the drug disinhibits T-cells, it can trigger severe, immune-mediated inflammatory reactions in healthy organs. These include pneumonitis (lung inflammation), hepatitis (liver enzyme elevation), colitis (severe diarrhea/intestinal inflammation), nephritis (kidney dysfunction), and endocrinopathies (hypothyroidism, hyperthyroidism, type 1 diabetes, or adrenal insufficiency).
Infusion-Related Risks: Infusion site complications or severe, systemic hypersensitivity reactions can occur during or immediately following intravenous administration.
Embryo-Fetal Toxicity: Fetal exposure can result in significant developmental harm.
Effective contraception must be confirmed and maintained during treatment and for a minimum of 3 months following the final infusion.
π¦ Cold-Chain Storage & Packaging Integrity
To safeguard biological potency and prevent protein degradation during international transit:
Strict Temperature Compliance: Must be continuously kept under refrigeration at 2Β°C to 8Β°C (36Β°F to 46Β°F).
Never allow the product to freeze or experience severe thermal shocks. Light Mitigation: Protect the solution from prolonged exposure to direct light or UV radiation by storing the vial inside its original factory box until the moment of clinical dilution.
Commercial Presentation: Supplied as a single-use vial providing 120 mg of Durvalumab in 2.4 mL of solution (concentration of 50 mg/mL).
π Bulk Logistics & Indian Export Excellence
Validated Cold-Chain Routing: Ernest Impex ensures complete supply-chain visibility by utilizing temperature-monitored, validated cold-chain shipping containers equipped with advanced data-loggers to preserve Imfinzi's viability from warehouse to destination.
AstraZeneca Product Authenticity: Every batch is sourced strictly through authorized distribution pathways, ensuring complete legitimacy, uncompromised structural integrity, and verified batch credentials.
Streamlined Documentation Dossier: Wholesale procurement shipments arrive equipped with precise commercial invoices, packing lists, tracking configurations, Certificates of Analysis (COA), and country-specific customs files.
PRESCRIPTION MEDICINE : YES
Disclaimer: Imfinzi 120mg Injection is a strictly controlled, high-potency prescription biological therapeutic. It must be prepared and administered exclusively under the direct prescription, guidance, and continuous monitoring of an oncologist or hematologist within an equipped clinical facility. The commercial data displayed here is intended solely for B2B procurement research, global institutional sourcing, and international logistics planning; it does not replace professional medical advice, clinical patient diagnosis, or direct medical consultation.
π Contact Ernest Impex β Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
π Websites:
π§ Email:
exports@ernestpharmaceuticals.com π¦ Business Type: Exporter | Bulk Supplier | Distributor
π² WhatsApp: +91 93599 02383
π² WhatsApp Link:
https://wa.me/919359902383
